Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.72
+0.86 (3.60%)
Apr 17, 2026, 4:00 PM EDT - Market closed
Pacira BioSciences Revenue
In the year 2025, Pacira BioSciences had annual revenue of $726.41M with 3.63% growth. Pacira BioSciences had revenue of $196.87M in the quarter ending December 31, 2025, with 5.14% growth.
Revenue (ttm)
$726.41M
Revenue Growth
+3.63%
P/S Ratio
1.38
Revenue / Employee
$876,250
Employees
829
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 726.41M | 25.45M | 3.63% |
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
| Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
| Dec 31, 2018 | 337.28M | 50.65M | 17.67% |
| Dec 31, 2017 | 286.63M | 10.26M | 3.71% |
| Dec 31, 2016 | 276.37M | 27.37M | 10.99% |
| Dec 31, 2015 | 249.00M | 51.33M | 25.97% |
| Dec 31, 2014 | 197.67M | 112.12M | 131.05% |
| Dec 31, 2013 | 85.55M | 46.47M | 118.89% |
| Dec 31, 2012 | 39.08M | 23.40M | 149.12% |
| Dec 31, 2011 | 15.69M | 1.13M | 7.74% |
| Dec 31, 2010 | 14.56M | -444.00K | -2.96% |
| Dec 31, 2009 | 15.01M | 1.08M | 7.76% |
| Dec 31, 2008 | 13.93M | 5.58M | 66.95% |
| Dec 31, 2007 | 8.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.25B |
| Evotec SE | 925.65M |
| Tilray Brands | 858.28M |
| Collegium Pharmaceutical | 780.57M |
| Amphastar Pharmaceuticals | 719.89M |
| Alvotech | 588.90M |
| Ironwood Pharmaceuticals | 296.15M |
| Harrow | 272.30M |
PCRX News
- 3 days ago - Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026 - GlobeNewsWire
- 6 days ago - Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures - GlobeNewsWire
- 11 days ago - Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 20 days ago - Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - PRNewsWire
- 5 weeks ago - Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - GlobeNewsWire
- 6 weeks ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - GlobeNewsWire